vTv Therapeutics Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of vTv Therapeutics Inc Company

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.

vTv Therapeutics Inc Info



Ticker SymbolVTVT

Company namevTv Therapeutics Inc

IPO dateJul 30, 2015

CEOMr. Paul Jai Sekhri

Number of employees23

Security typeOrdinary Share

Fiscal year-endJul 30

Address3980 Premier Dr

CityHIGH POINT

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code27265

Phone13368410300

Websitehttps://vtvtherapeutics.com/

Ticker SymbolVTVT

IPO dateJul 30, 2015

CEOMr. Paul Jai Sekhri

Company Executives of vTv Therapeutics Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

--

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

--

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

--

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

--

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

--

Mr. Burns Mcclellan

Investor Relations

--

Dr. Michael Tung, M.D.

Executive Vice President, Chief Financial Officer

--

Mr. Daniel (Dan) Spiegelman

Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

--

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

--

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

--

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

--

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

--

Revenue Breakdown

FY2023

No Data

By RegionUSD

Name

Revenue

Proportion

United States

0.00

0.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Sat, Sep 13

Shareholders

Shareholder Types

Shareholders

Proportion

MacAndrews & Forbes Holdings, Inc.

34.88%

Samsara BioCapital, LLC

11.95%

Trails Edge Capital Partners LP

8.83%

Fidelity Management & Research Company LLC

6.81%

Invus Public Equities LP

6.23%

Other

31.30%

Shareholders

Proportion

MacAndrews & Forbes Holdings, Inc.

34.88%

Samsara BioCapital, LLC

11.95%

Trails Edge Capital Partners LP

8.83%

Fidelity Management & Research Company LLC

6.81%

Invus Public Equities LP

6.23%

Other

31.30%

Shareholder Types

Shareholders

Proportion

Holding Company

34.88%

Investment Advisor

24.03%

Venture Capital

11.95%

Hedge Fund

6.61%

Investment Advisor/Hedge Fund

1.09%

Individual Investor

0.63%

Other

20.81%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

47

1.14M

43.69%

+560.06K

2025Q2

54

1.51M

57.66%

-17.51K

2025Q1

53

1.53M

60.03%

+1.63K

2024Q4

55

1.51M

61.92%

-7.51K

2024Q3

55

1.49M

61.31%

+181.69K

2024Q2

53

1.29M

53.13%

+308.00

2024Q1

64

1.68M

72.07%

+129.32K

2023Q4

64

1.40M

68.78%

-52.49K

2023Q3

72

1.41M

69.35%

-49.61K

2023Q2

81

1.40M

81.32%

+323.67K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

MacAndrews & Forbes Holdings, Inc.

912.98K

34.88%

--

Apr 01, 2025

Samsara BioCapital, LLC

312.78K

11.95%

+106.00K

+51.26%

Sep 22, 2025

Trails Edge Capital Partners LP

231.00K

8.83%

+231.00K

--

Aug 29, 2025

Fidelity Management & Research Company LLC

178.20K

6.81%

--

Jun 30, 2025

Invus Public Equities LP

163.00K

6.23%

+163.00K

--

Aug 29, 2025

Baker Bros. Advisors LP

148.31K

5.67%

+51.00K

+52.41%

Sep 03, 2025

The Vanguard Group, Inc.

43.17K

1.65%

+1.62K

+3.89%

Jun 30, 2025

Northern Trust Investments, Inc.

15.29K

0.58%

-339.00

-2.17%

Jun 30, 2025

Millennium Management LLC

15.04K

0.57%

+15.04K

--

Jun 30, 2025

Geode Capital Management, L.L.C.

12.87K

0.49%

+229.00

+1.81%

Jun 30, 2025

Related ETFs



Updated: 2 hours ago

Name

Proportion

iShares Micro-Cap ETF

0.01%

iShares Core S&P Total U.S. Stock Market ETF

0%

iShares Micro-Cap ETF

Proportion0.01%

iShares Core S&P Total U.S. Stock Market ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Date

Type

Ratio

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1